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Abstract
In 2011, the World Health Organization’s (WHO) mental
health Gap Action Programme (mhGAP) released
evidence-based epilepsy-care guidelines for use in low
and middle income countries (LAMICs). From a
geographical, sociocultural, and political perspective,
LAMICs represent a heterogenous group with significant
differences in the epidemiology, etiology, and
perceptions of epilepsy. Successful implementation of
the guidelines requires local adaptation for use within
individual countries. For effective implementation and
sustainability, the sense of ownership and empowerment
must be transferred from the global health authorities to
the local people. Sociocultural and financial barriers that
impede the implementation of the guidelines should be
identified and ameliorated. Impact assessment and
program revisions should be planned and a budget
allocated to them. If effectively implemented, as
intended, at the primary-care level, the mhGAP
guidelines have the potential to facilitate a substantial
reduction in the epilepsy treatment gap and improve the
quality of epilepsy care in resource-limited settings.
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Introduction
Epilepsy is a major global healthcare issue. An estimated
70 million people worldwide live with epilepsy [1,2],
most of whom remain untreated [3]. To improve epi-
lepsy-care services, most developed countries adopted
national guidelines at least a decade ago, with these being
regularly updated [4-6]. Whenever possible, such guide-
lines are evidence-based, relying upon the body of
evidence for best care practices in high-income,
resource-rich countries with predominantly moderate cli-
mates. However, 80% of people with epilepsy (PWE) live
in so-called ‘developing’, low-income, or resource-poor
countries in tropical or subtropical regions[1]. For many
reasons including resource restrictions, simply adopting
healthcare guidelines created for higher-resourced areas
and using these in resource-limited settings is neither
appropriate nor feasible [7]. Unfortunately, such settings
generally lack sufficient neurologic expertise and/or
advocacy for the development and implementation of
epilepsy-care guidelines. The World Health Organization
(WHO) recently released evidence-based, epilepsy-care
guidelines appropriate for use in resource-limited, tropi-
cal settings [8,9]. Implementation of the WHO mental
health Gap Action Programme (mhGAP) guidelines will
require local adaptation for use within individual coun-
tries, but if effectively implemented as intended at the
primary-care level, the mhGAP guidelines could facilitate
a substantial reduction in the epilepsy treatment gap and
improve the quality of care received by PWE in resource-
limited settings. Effective guidelines require local adapta-
tion, implementation, impact assessment, and program
revision. The challenges to these important processes are
substantial.
World Health Organization Mental Health Gap Action
Programme guideline development
Low-income and high-income regions differ substantially
in terms of the underlying etiologies of epilepsy, the exper-
tise of the healthcare personnel, and the diagnostic capa-
city, treatment options, and cultural perception of the
disorder (Table 1). Guidelines for use in the resource-poor
environments must address factors specific for the clinical
and sociocultural setting (Table 2). Valid guidelines are of
paramount importance for low-income tropical regions as
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the mortality associated with epilepsy in such regions may
be relatively high even when there is treatment available
[10], and the treatment gap remains vast, with less than
20% of people with active epilepsy in most developing
countries receiving treatment [11].
Guidelines developed in high-income countries are likely
to be inappropriate for use in LAMICs [7]. In general, the
transferability of evidence derived from studies conducted
in high- income countries to LAMICS is dubious [7,12,13].
Differences in patient populations and healthcare systems
are so prominent that the evidence may not be valid [7,14];
hence, the development of guidelines specifically crafted
for resource-limited settings is the best strategy.
In 1977, the WHO, in collaboration with the Interna-
tional League against Epilepsy and the International Bureau
for Epilepsy, launched the Global Campaign Against
Epilepsy to improve the care of PWE in resource-poor
countries [15]. In 2008, WHO began development of evi-
dence-based guidelines for epilepsy and seizure care in
LAMICs [8,16], and these guidelines were released in 2011.
Local adaptation of the guidelines
The clinical care algorithms provided in the mhGAP
were developed for use in a wide range of possible
low-income and middle- income settings, and therefore
must be adapted to local resources and needs, especially
if the guidelines are to be used by the non-physician
healthcare workers who provide most primary healthcare
services in such settings. From the geographical, socio-
cultural, and political viewpoints, countries previously
termed ‘developing’ represent a markedly heterogenous
group. The epilepsy burden is different in Asia, Latin
America, and sub-Saharan Africa [17], and even within
one area, such as sub-Saharan Africa, there are significant
variations in the epidemiology, etiologies, and percep-
tions of epilepsy in different geographical regions and
communities [18]. The process of adaption also offers the
opportunity to further foster a sense of ownership and
empowerment among local health authorities [19].
The most feasible and cost-effective way to deliver epi-
lepsy care in LAMICs is through the use of inexpensive
antiepileptic drugs (AEDs) delivered by non-physician
healthcare workers at the primary-care level [20]. Clinical
case definitions for epileptic seizures and epilepsy used for
guideline application must consider the limited neurologic
expertise of primary-care providers, lack of diagnostic
options, and the local syntactic/semantic language used
for describing seizure symptoms, as well as the time frame
Table 1 Critical differences affecting health and health care in high-income versus low-income and middle-income
countries [19,23]
High-income countries Low-income and middle-income countries
Gross national income
per capita
High ≥US$9,386; upper middle US$3,036 to $9,385 Low ≤US$765 or lower; middle US$766 to $3,035
Access to health care Initial access usually through primary care with
established referral networks, which may include high
indirect costs
Limited to very basic primary care especially in rural areas and/or
established referral networks, which invariably include high
indirect costs
Healthcare funding National programs, private insurance, out-of-pocket
expenses
Often ill-funded, may rely on donors/volunteering services.




Neoplastic, cerebrovascular (Post-)infectious, antenatal, post-traumatic
HIV prevalence Low Can be moderate to high
Cultural perception of
seizures




Neutral public perception or at least social
presentation of neutrality
Overt negative public perception, stigmatization, and
discrimination common
Table 2 Realities and requirements for guidelines for low-income and middle- income countries
Reality Requirement
Care is largely provided by non-physician healthcare workers
with very basic or no neurological training
Clear case definition of epileptic seizures and simple algorithms tailored for the local
circumstances
Limited access to medication Guidelines recommending those medications that can be accessed
Indirect costs as a barrier to care-seeking and adherence Priority for inexpensive affordable drugs delivered as close to the patient’s residence
as possible
High prevalence of infectious causes Incorporate into guidelines testing/treating of common conditions such as HIV,
neurotuberculosis, and parasitosis. Refer to existing treatment guidelines whenever
possible unless comorbid conditions require care that differs from national
guidelines
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of the symptoms [21]. The mhGAP guidelines recognize
that in LAMICs, seizures are often caused by acute central
nervous system (CNS) infection or metabolic disorders.
Furthermore, epilepsy can be the first presentation of a
sub-acute or chronic CNS condition that might be amen-
able to treatment in resource-poor environment [20].
Hence, local adaptation of mhGAP guidelines must con-
sider the local epidemiology of potential underlying
seizure etiologies [20,22].
Local adaptation must also address any special circum-
stances within a specific country. For example, where
HIV rates are high, a significant proportion of PWE can
be expected to also have co-morbid HIV infection. If the
available AEDs are limited to enzyme-inducing agents,
potential interactions between AEDs and antiretroviral
medications must be considered, and treatment options
appropriate for dual therapy must be made available
[23,24]. Guidelines for epilepsy care in resource-limited
settings by non-physician healthcare workers must also
specifically address injury prevention and, if applicable,
fears of contagion [10]. The adapted content of such pro-
grams must be directed by local practices, injury risk
factors, and beliefs.
The development of national programs in LAMIC
should be paralleled by clinical research increasing our
knowledge of epilepsy beyond high-income regions. Such
research would facilitate the development of a new multi-
dimensional classification of epilepsy applicable to a wide
range of settings including LAMIC [25,26].
Implementing guidelines in low-income and middle-
income countries
Passive dissemination of guidelines is on its own insuffi-
cient to ensure appropriate uptake of recommendations
[27]. Sociocultural and financial barriers impede the
implementation of guidelines in all healthcare settings.
Within LAMICs, strong advocacy for guideline adoption
by health authorities at the national, provincial, district,
and institutional levels are required [27]. Barriers at the
patient, healthcare worker and macro level threaten the
implementation of guidelines [23]. True advocacy
requires that local healthcare authorities prioritize epi-
lepsy care sufficiently highly to guarantee that the basic
materials and training required to adhere to the guide-
lines are provided to healthcare workers at every level of
care for which they are intended. If care equity is to be
Clear case definitions of epileptic seizures and epilepsy, tailored for use by 
non-physician healthcare workers 
User-friendly guidelines adapted for local environment, based on local 
diagnostic capacity and with input from local experts and stakeholders  
Active dissemination of guidelines with workshops appropriate for resource-
low setting 
Implementation of the guidelines within the framework of the existing 
healthcare delivery system. Should include using the guidelines for testing for 
treatable causes of epilepsy  
Meticulous evaluation of guidelines which include local researchers and 
provides feedback to the local stakeholders as well as the WHO 
 
Figure 1 Primary principles for developing guidelines for epilepsy care in low-income countries.
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achieved, special attention must be focused on the imple-
mentation of the guidelines in poorer rural areas, because
residency in a rural region is an independent risk factor
for poor access to treatment [3].
Particularly in rural areas, ‘buy-in’ from local stake-
holders is of paramount importance. This requires
seeking active input from local communities in devel-
oping national priorities and programs at an early
stage. Such stakeholders should also be involved the
program-evaluation process. Important local stake-
holders may include individuals such as traditional hea-
lers, who are often the de facto care providers for PWE
[28]. Whenever possible, collaborations that do not
compromise patient care and safety should be sought.
Provoking a culture clash between traditional and
‘western-type ’ medicine is unlikely to benefit the
patient with epilepsy.
Impact assessment
As guidelines are being implemented, program evalua-
tions to assess their operational performance in clinical
practice and their effects on care quality should be con-
currently planned and budgeted [29]. As in more medi-
cally developed countries [30], low-income countries
need valid quality indicators for epilepsy care that can
adequately assess the effects of guideline implementa-
tion. It may be possible to develop such quality indica-
tors even with basic health records in some LAMIC
institutions [31]. Before initial implementation, plans
should be discussed for updating guidelines as needed
and revising them based upon the findings of the impact
assessment. Special consideration should also be given
to any potential unintended consequences of the guide-
lines. For example, if a guideline refers to additional
diagnostic studies, is it possible for primary-care workers
to delay necessary seizure treatment while waiting for an
electroencephalogram or neuroimaging, when access to
such studies are limited and the logistics of study acqui-
sition are challenging?
Conclusion
The mhGAP guidelines need to be adapted for country-
specific use in LAMICs. These baseline recommenda-
tions can facilitate the development of national guide-
lines and the establishment of national epilepsy
programs tailored to the existing healthcare setting. The
locally relevant guidelines should then be critically eval-
uated and amended if necessary, based on the results of
the assessment (Figure 1). Evaluations are needed to
ensure that the guidelines are practical, evidence-based.
and cost-effective [32,33]. Training resources (including
sample pathways and video training) adapted for local
primary-care settings should be expanded to facilitate
the acceptance and successful implementation of the
guidelines [9]. The implementation of epilepsy guide-
lines could result in a decrease in the burden of epilepsy
worldwide [16].
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